The Lancet Haematology
Fecha de publicación: June 2018
DOI: https://doi.org/10.1016/S2352-3026(18)30065-6
Autores: Andrés José María Ferreri
Background: Diffuse large B-cell lymphoma is diagnosed in elderly patients with increasing frequency, with 40% of diagnoses now made in patients older than 70 years. Combination therapy based on anthracycline and rituximab (ie, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) is the standard treatment regimen for diffuse large B-cell lymphoma.
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.